Long-term Follow-up of Patients Previously Treated With Autologous T Cells Genetically Modified With Retroviral Vectors
Phase of Trial: Phase II/III
Latest Information Update: 08 Aug 2019
Price : $35 *
At a glance
- Drugs AUTO 2 (Primary) ; AUTO-3 (Primary) ; AUTO-4
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Autolus
- 08 Aug 2019 According to an Autolus media release, the company expects to present data from the study at ASH 2019.
- 14 May 2019 According to an Arix Bioscience media release, updated data from this study is expected at the end of this year.
- 06 Sep 2018 New trial record